Company intelligence / Profile preview

Stablepharma

Ownership: Private
Development stage: Other

Overview

Stablepharma has received MHRA approval for Phase 1 clinical trials of SPVX02, a fridge-free Tetanus and Diphtheria (Td) vaccine. Trials commenced in early April 2025 at the National Institute for Health and Care Research (NIHR) Southampton Clinical Research Facility[3].

Therapeutic areas: Infectious Diseases
Modalities: VaccinesPharmaceuticals
Industry: Biotech

Drug pipeline

6 assets

SPVX02

5 more assets in the full pipeline.

Partnerships

Thermo Fisher ScientificNational Institute for Health and Care Research (NIHR) Southampton Clinical Research Facility

Beyond the preview

Go deeper on Stablepharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Stablepharma.